Current States of Clinical Perspectives on Medication for Dyslipidemia

Current topics for dyslipidemia are described. Elderly people receiving statin (n=326,981) for 6.8 years showed reduced hazard ratio (HR) as total mortality 0.75, and cardiovascular mortality 0.80. Taking n-3 unsaturated fatty acids >3g daily reduced relative ratio (RR) as sudden death 0.70, stroke 0.74 and cardiac death 0.82. As LDL-C is reduced every 1.0 mmol/L (38.67 mg/dL), cardiovascular event will be reduced by 21%. The efficacy of inclisiran has been reported for reducing LDL-C value. In large RCTs of ORION 10/11 studies, patients with atherosclerotic cardiovascular disease (ASCVD) receiving inclisiran for 510 days showed decreased LDL-C ratio as 53.8%/49.2%.

This is an open-access article distributed under the terms of the Creative Commons Attribution License(https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.